Suppr超能文献

Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.

作者信息

Gonzalez M A, Moranchel A H, Duran S, Pichardo A, Magana J L, Painter B, Forrest A, Drusano G L

出版信息

Antimicrob Agents Chemother. 1985 Aug;28(2):235-9. doi: 10.1128/AAC.28.2.235.

Abstract

We administered multiple doses of ciprofloxacin intravenously over 30 min every 12 h for 1 week to nine healthy volunteers. Three volunteers received a placebo (vehicle) intravenously. Doses of 100, 150, and 200 mg were evaluated with a 1-week wash-out period intervening between each dose level. Terminal excretion half-lives averaged 3.67 +/- 0.65, 3.60 +/- 0.26, and 4.00 +/- 0.69 h for the 100-, 150-, and 200-mg doses, respectively. Serum clearances were 30.1 +/- 3.4, 29.8 +/- 4.0, and 26.9 +/- 4.1 liters/h per 1.73 m2 for these doses. Urine concentrations remained in excess of the MIC for 90% of the relevant urinary tract pathogens for the full 12-h dosing interval at each dose. Renal clearance accounted for 56 to 71% of the serum clearance. However, because a microbiologic assay was used and biologically active, renally excreted metabolites were identified, the renal clearance determinations are likely to be in excess of the true values. The doses of ciprofloxacin administered intravenously were well tolerated, and the drug concentrations appeared adequate for the treatment of the vast majority of cases of nosocomially acquired sepsis and urinary tract infections. For patients with serious Pseudomonas infections and perhaps staphylococcal infections, either an 8-h dosing schedule or larger doses on a 12-h schedule should be considered.

摘要

相似文献

1
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.
Antimicrob Agents Chemother. 1985 Aug;28(2):235-9. doi: 10.1128/AAC.28.2.235.
2
Multiple-dose ciprofloxacin dose ranging and kinetics.
Clin Pharmacol Ther. 1985 Jun;37(6):633-7. doi: 10.1038/clpt.1985.102.
3
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
Antimicrob Agents Chemother. 1984 Nov;26(5):741-4. doi: 10.1128/AAC.26.5.741.
4
Pharmacokinetics of intravenously administered ciprofloxacin.
Antimicrob Agents Chemother. 1984 Aug;26(2):208-10. doi: 10.1128/AAC.26.2.208.
5
Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses.
Antimicrob Agents Chemother. 1986 Jan;29(1):62-6. doi: 10.1128/AAC.29.1.62.
6
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
Antimicrob Agents Chemother. 1987 Jun;31(6):860-4. doi: 10.1128/AAC.31.6.860.
8
Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses.
Eur J Clin Microbiol. 1986 Apr;5(2):187-92. doi: 10.1007/BF02013984.
9
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
Antimicrob Agents Chemother. 1985 Mar;27(3):375-9. doi: 10.1128/AAC.27.3.375.
10
The pharmacology of orally administered ciprofloxacin.
Drugs Exp Clin Res. 1985;11(5):339-41.

引用本文的文献

1
3
Melting curve analysis for rapid detection of topoisomerase gene mutations in Haemophilus influenzae.
J Clin Microbiol. 2009 Mar;47(3):781-4. doi: 10.1128/JCM.01645-08. Epub 2009 Jan 7.
5
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.
Clin Pharmacokinet. 2001;40(3):169-87. doi: 10.2165/00003088-200140030-00003.
6
Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis.
Antimicrob Agents Chemother. 2000 Jun;44(6):1674-9. doi: 10.1128/AAC.44.6.1674-1679.2000.
7
Quinolones in the elderly.
Drugs. 1995;49 Suppl 2:112-4. doi: 10.2165/00003495-199500492-00017.
8
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.
Antimicrob Agents Chemother. 1993 May;37(5):1065-72. doi: 10.1128/AAC.37.5.1065.
9
Absolute oral bioavailability of ciprofloxacin.
Antimicrob Agents Chemother. 1986 Sep;30(3):444-6. doi: 10.1128/AAC.30.3.444.
10
Pharmacokinetics of ciprofloxacin in cystic fibrosis.
Antimicrob Agents Chemother. 1987 Jun;31(6):915-9. doi: 10.1128/AAC.31.6.915.

本文引用的文献

1
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.
Antimicrob Agents Chemother. 1984 Mar;25(3):331-5. doi: 10.1128/AAC.25.3.331.
2
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
Antimicrob Agents Chemother. 1984 Nov;26(5):741-4. doi: 10.1128/AAC.26.5.741.
3
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
Antimicrob Agents Chemother. 1984 May;25(5):633-7. doi: 10.1128/AAC.25.5.633.
4
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
Antimicrob Agents Chemother. 1984 Mar;25(3):319-26. doi: 10.1128/AAC.25.3.319.
5
Simplified, accurate method for antibiotic assay of clinical specimens.
Appl Microbiol. 1966 Mar;14(2):170-7. doi: 10.1128/am.14.2.170-177.1966.
6
7
A program package for simulation and parameter estimation in pharmacokinetic systems.
Comput Programs Biomed. 1979 Mar;9(2):115-34. doi: 10.1016/0010-468x(79)90025-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验